ArticleOncoimmunology2025

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Hayato Kawachi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.